Importance of supplying L-carnitine for patients with hepatocirrhosis - research on improvement of MHE-

Importance of supplying L-carnitine for patients with hepatocirrhosis - research on improvement of MHE- - Importance of supplying L-carnitine for patients with hepatocirrhosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009477

Enrollment

Registered

2012-12-05

Start date

2012-12-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocirrhosis

Interventions

taking L-carnitine(600mg) orally three times in a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient that an agreement is provided in a document about this study for decompensated cirrhosis 20 years or older

Exclusion criteria

Exclusion criteria: 1.The patient who has difficulty in continuation of the treatment 2.The patient who judged that the chief physician had difficulty with a trial entry

Design outcomes

Primary

Measure	Time frame
Improvement of MHE(by NP test)	—

Secondary

Measure	Time frame
1.Change of serum L-carnitine classification 2.Improvement of QOL(assessment by CLDQ) 3.Change of serum amino acidsclassification	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026